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ess: tmd5@cwru.edu.Summary Tuberculosis has claimed its victims throughout much of known human
history. It reached epidemic proportions in Europe and North America during the
18th and 19th centuries, earning the sobriquet, ‘‘Captain Among these Men of
Death.’’ Then it began to decline. Understanding of the pathogenesis of tuberculosis
began with the work of The´ophile Laennec at the beginning of the 19th century and
was further advanced by the demonstration of the transmissibility of Mycobacterium
tuberculosis infection by Jean-Antoine Villemin in 1865 and the identiﬁcation of the
tubercle bacillus as the etiologic agent by Robert Koch in 1882. Clemens von Pirquet
developed the tuberculin skin test in 1907 and 3 years later used it to demonstrate
latent tuberculous infection in asymptomatic children. In the late 19th and early
20th centuries sanatoria developed for the treatment of patients with tuberculosis.
The rest provided there was supplemented with pulmonary collapse procedures
designed to rest infected parts of lungs and to close cavities. Public Health measures
to combat the spread of tuberculosis emerged following the discovery of its bacterial
cause. BCG vaccination was widely employed following World War I. The modern era
of tuberculosis treatment and control was heralded by the discovery of streptomycin
in 1944 and isoniazid in 1952.
& 2006 Published by Elsevier Ltd.Tuberculosis is an ancient scourge. It has plagued
humankind throughout known history and human
prehistory. It has surged in great epidemics and
then receded, thus behaving like other infectious
diseases, but with a time scale that challenges
accepted explanations for epidemic cycles. Myco-
bacterium tuberculosis may have killed more
persons than any other microbial pathogen.Published by Elsevier Ltd.One can hypothesize that the genus Mycobacter-
ium originated more than 150 million years ago.1
Mycobacterium ulcerans has speciﬁc habitat re-
quirements and a current geographic distribution
that separates its endemic regions widely. Those
regions were last in contiguity as part of the
Gondwanaland continental land mass during the
Jurassic period. Modern techniques of molecular
genetics and the sequencing of the genome of
several strains of M. tuberculosis allow a more
rigorous estimation of the time of origin of
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low mutation rate of M. tuberculosis. Gutierrez and
her colleagues concluded that an early progenitor
of M. tuberculosis was present in East Africa as
early as 3 million years ago, and they suggest that it
may have infected early hominids at that time.2 It
is likely, however, that all modern members of
the M. tuberculosis complex, including not only
M. tuberculosis but its African variants Mycobacter-
ium africanum and Mycobacterium canettii as well
as Mycobacterium bovis, had a common African
ancestor about 35,000–15,000 years ago.2–4 Modern
strains of M. tuberculosis appear to have originated
from a common ancestor about 20,000–15,000
years ago.5 Currently circulating strains fall into
six major lineages, or clades, all of which are
present in East Africa; their global distribution
varies, however.6 Analysis based on the known
mutation rate of M. tuberculosis indicates that
much of the present diversity among these strains
originated between 250 and 1000 years ago.7
East Africa was, then, the ancestral home of both
tubercle bacilli and its human hosts. Archeological
evidence for any disease is generally lacking in East
Africa. However, tuberculosis in Egypt can be
documented more than 5000 years ago. Typical
skeletal abnormalities of tuberculosis, including
characteristic Pott’s deformities, have been found
in Egyptian mummies and are clearly depicted
in early Egyptian art.8–11 Among the early descrip-
tions of Egyptian tuberculosis was that of A.J.E.
Cave, published in 1939 in the British Journal of
Tuberculosis.8 More recently, M. tuberculosis DNA
has been ampliﬁed from tissues of Egyptian
mummies leaving no doubt as to the cause of early
skeletal disease.12,13 Written record of Egyptian
tuberculosis is limited. No reference to it is present
in medical papyri, although the descriptions of
diseases in these records is not easily deciphered.8
Tuberculosis is clearly noted in the Biblical books of
Deuteronomy and Leviticus, however, using the
ancient Hebrew word schachepheth.14 Tuberculosis
was well established in East Africa by the time
Europeans reached the area in the 19th century.15
Early people began to move out of Africa as early
as 1.7 million years ago, but these early migrants
were largely replaced by later waves of humans
during the past 35,000–89,000 years.16 One can
assume that they took their diseases, including
tuberculosis, with them. There are written texts
describing tuberculosis in India as early as 3300
years ago and in China 2300 years ago.10,17
Wandering humans reached Europe and Asia easily,
but their move into the Americas was blocked by
the Bering Strait. In fact, a land bridge existed
connecting Siberia and Alaska until about 10,000years ago, but this route was largely blocked by
glacial ice between about 30,000 and 12,000 years
ago. Thus, early venturers into the Western Hemi-
sphere, had limited times in which they could
travel by land, but coastal water travel was open to
them more generally. Although there remains some
disagreement about its precise dating, the Monte
Verde site in Chile probably puts human occupation
of that South American area as early as 33,000
years ago, with evidence of a tool-making commu-
nity as early as 12,500 years ago.18
Just as in Egypt, archeological evidence of early
tuberculosis is found in America.18–21 Bony tuber-
culosis, including Pott’s disease is well demon-
strated in Peruvian mummies. And as in Egypt,
M. tuberculosis DNA has been recovered from
mummiﬁed tissues. While the earliest evidence of
pre-Columbian tuberculosis in America comes from
the Andean Region, there is abundant archeological
evidence that the disease occurred throughout the
hemisphere prior to the arrival of the ﬁrst European
explorers.18,22
Tuberculosis was well known in classical Greece,
where it was called phthisis, N24FH.23,24 Hippo-
crates clearly recognized tuberculosis and under-
stood its clinical presentation. ‘‘Phthisis makes its
attacks chieﬂy between the age of eighteen and
thirty-ﬁve,’’ he wrote in his aphorisms, clearly
recognizing the predilection of young adults for
active tuberculosis.25 ‘‘Consumption was the most
considerable of the diseases which then prevailed,
and the only one which proved fatal to many
persons,’’ he wrote in Book I, Of the Epidemics.26
At that time, however, tuberculosis appears not to
have been a problem in Alexandria; the African
epidemic had waned, at least in Egypt.24 The Greek
physician, Clarissimus Galen, became physician to
Roman Emperor Marcus Aurelius in 174. He wrote of
tuberculosis and recommended fresh air, milk, and
sea voyages for its treatment, but the disease does
not have prominence in his medical texts.
As Europe entered the middle ages, the written
record of tuberculosis becomes sparse. That does
not mean that the disease was not present. Indeed,
there is archeologic evidence from widespread sites
throughout Europe for tuberculosis during the
millennium that followed the fall of Rome in the
5th century.22 St. Francis of Assisi died in 1226 at
the age of 44, probably of tuberculosis.27 A
fascinating aspect of tuberculosis during the middle
ages is that of scrofula, which European monarchs
beginning with Clovis in 496 treated with the ‘‘royal
touch.’’ Hundreds, and sometimes thousands, of
scrofulous individuals were touched by monarchs
during the next several hundred years, and a
codiﬁed ritual for conﬁrming the diagnosis and
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church.24 Queen Anne was the last British ruler to
touch for scrofula; a young Samuel Johnson was
among those upon whom she laid her hands.
As the renaissance swept northward from Italy
into Northern Europe, new knowledge emerged,
including new knowledge of disease. The great
anatomists of Padua were supplanted at the helm
of medicine by French giants Jean Nicolas Corvi-
sart, Marie-Franc-ois-Xavier Bichat, Gaspard Laur-
ent Bayle, and Rene´ The´ophile Hyacinthe Laennec.
It was Laennec, most frequently remembered today
for his invention of the stethoscope, who clearly
elucidated the pathogenesis of tuberculosis and
uniﬁed the concept of the disease, whether
pulmonary or extrapulmonary.28–30 His 1819 book,
D’Auscultation Mediate, was translated into English
with considerable editing by John Forbes in 1821.31
In this work Laennec not only clearly expounded
the pathology of tuberculosis but also described
most of the physical signs of pulmonary disease and
introduced terms to describe those ﬁndings that are
still in use today. Modern understanding of tuber-
culosis began with Laennec’s treatise.
Laennec’s work was possible in large part because
of his enormous experience with autopsies of
persons dying of tuberculosis at the Hoˆpital Necker
in Paris. By Laennec’s era, tuberculosis had surged
across Europe in an epidemic tsunami. Death rates
in London, Stockholm, and Hamburg approached
800–1000/100,000/year at that time.32,33 Nor was
North America spared. Similar death rates prevailed
in American cities of the time.34
In the face of such an awesome tuberculosis
prevalence, society responded by romanticizing the
disease. The wan and pallid facies of the victim of
tuberculosis were thought to be attractive.
Georges Sand, Fre´de´ric Chopin’s lover, called him
her ‘‘poor melancholy angel.’’ Poet George Lord
Byron, who did not himself have tuberculosis, is
said to have remarked to a friend, ‘‘I should like to
die of a consumption.’’ ‘‘Why?’’ countered his
friend. ‘‘Because the ladies would all say, ‘Look at
that poor Byron, how interesting he looks in
dying!.’’’35 Emily Bronte¨ described the tuberculous
heroine in Wuthering Heights as ‘‘rather thin, but
young and fresh complexioned and her eyes
sparkled as bright as diamonds.’’36 Charles Dickens
wrote in describing the death of Smike in Nicholas
Nickleby, ‘‘[As] the mortal part wastes and withers
away, so the spirit grows light and sanguine.’’37
When commissioned in 1883 to create his famous
statue of John Harvard, who gave his name to
Harvard University, sculptor Daniel Chester French
found there were no existing pictures of Harvard.
‘‘But it is recorded,’’ he noted, ‘‘that he died at theage of about thirty of consumptiony. It is fair to
assume that his face would be delicate in modeling
and sensitive in expression.’’38
Surrounded by patients with tuberculosis, med-
ical practitioners and scientists struggled to under-
stand its etiology. In Northern Europe tuberculosis
was generally considered a heritable disease; in
Southern Europe it was felt to be infectious in
nature. This dichotomy of views was expressed by
Georges Sand in a letter to Francois Rollinat written
in 1838 from Mallorca, where she and Chopin had
gone hoping the climate would improve Chopin’s
failing health. They were expelled from Palma by a
concerned citizenry, ‘‘phthisis being extremely rare
in those latitudes and, moreover, considered con-
tagious!.’’39 That tuberculosis was, indeed, infec-
tious in nature was probably ﬁrst suggested in 1790
by Benjamin Marten, who attributed the disease to
‘‘some certain species of animalcula.’’40 French
military surgeon Jean-Antoine Villemin convin-
cingly demonstrated the infectious nature of
tuberculosis in 1865 when he inoculated a rabbit
with ‘‘a small amount of purulent liquid from a
tuberculous cavity’’ removed at autopsy from an
individual who had died of tuberculosis.26 Although
the animal remained outwardly healthy, it was
found to have extensive tuberculosis when sacri-
ﬁced and autopsied 3 months later. Rabbits,
as it happens, are generally resistant to infection
with M. tuberculosis; Villemin’s results might have
been even more dramatic had he chosen to
inoculate a guinea pig. About the same time,
William Budd wrote a letter to Lancet suggesting
that tuberculosis ‘‘is disseminated through society
by speciﬁc germsy cast off by personsy suffering
from the disease.41 Evidently unaware of
Villemin’s work, he based his view on the then
known epidemiology of tuberculosis in naive popu-
lations.
The history of tuberculosis was changed drama-
tically on March 24, 1882, when Hermann Heinrich
Robert Koch made his justly famous presentation,
Die Aetiologie der Tuberculose, to the Berlin
Physiological Society.24,42,43 In his presentation,
Koch not only presented demonstrations of the
tubercle bacillus he had identiﬁed but posited
his famous postulates, perhaps better called the
Koch-Henle postulates, which to this day set
the standard for the demonstration of infectious
etiology. While a District Health Ofﬁcer in Wolstein,
Koch had previously elucidated the life cycle
of anthrax, earning an appointment at the Imperial
Health Ofﬁce in Berlin. Koch’s contributions to
bacteriology were legion, and he was awarded the
Noble Prize in Medicine or Physiology in 1905 for his
elucidation of the etiology of tuberculosis.
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International Medical Conference in Berlin in which
he said he had isolated a substance from tubercle
bacilli that could ‘‘render harmless the pathogenic
bacteria that are found in a living body and do this
without disadvantage to the body.’’44 He called this
substance tuberculin, and injections of it rapidly
came into vogue as a treatment for tuberculosis;
they were almost as rapidly discredited as ineffec-
tive. Koch injected himself with .25 cm3 of his
concentrated tuberculin and observed that he
developed ‘‘an unusually violent attack of ague
y and rise of body temperature up to 39.61C.’’45
He concluded that his tuberculin might be of use
diagnostically, and Danish veterinarians soon were
tuberculin-testing cattle.
In 1907, 33-year-old Clemens Freiherr von Pir-
quet was one of Vienna’s leading pediatricians. He
had already made the original recognition of serum
sickness, and he had coined the terms allergy and
allergen. He had ﬁrst observed and described
anamnestic (booster) immune responses. In 1907,
after learning of Koch’s reaction to his self-injected
tuberculin, he used a vaccination lancet to intro-
duce a small amount of diluted tuberculin intracu-
taneously.46,47 Two years later he published a more
extensive study of tuberculin reactions in which he
set forth a cut-point of 5mm and noted that
positive tuberculin reactions reﬂected latent tu-
berculosis (a term he introduced) in children who
did not manifest tuberculosis.48 Charles Mantoux
introduced the use of a cannulated needle and
syringe to inject tuberculin intracutaneously in
1908, and Florence Seibert developed puriﬁed
protein derivative (PPD) essentially in the form in
which it is currently used in a series of investiga-
tions at the Phipps Institute of the University of
Pennsylvania during the 1930s.
With the availability of well-standardized PPD,
careful studies of tuberculin reaction sizes became
possible, and such studies led to further knowledge
of mycobacterial infections. In 1952 Carroll Palmer
and Leroy Bates published a large study of reactions
to one test unit of PPD-S (equivalent to 0.4 units of
PPD-RT23) in more than 3000 hospitalized tubercu-
losis patients.49 Fewer than 1% failed to react.
Reactions sizes were normally distributed about a
mean and mode of 15mm; later studies with ﬁve
units of PPD-S would establish a mean of 17mm.
Three years later, a World Health Organization
study group published a report that expanded these
skin testing studies to school children in various
populations.50 While the distribution of reaction
sizes in tuberculous patients observed by Palmer
and Bates was conﬁrmed, this report showed that in
high tuberculosis prevalence countries—Ethiopiaand the Philippines, for example—a substantial
number of healthy school children reacted with
reaction sizes similar to those in tuberculous
patients. These children had latent tuberculous
infections, as ﬁrst noted by von Pirquet.48 In some
populations, they noted, reaction sizes in these
children were skewed towards smaller reactions.
That these smaller reactions were due to cross-
reacting hypersensitivity to the antigens of envir-
onmental mycobacteria was demonstrated experi-
mentally in guinea pigs by Edwards and Palmer.51
Ultimately Edwards and her colleagues performed
tuberculin skin tests of more than 600,000 United
States naval recruits.52 They established conclu-
sively that latent tuberculous infection is common
in the United States and preumably in other low
tuberculosis prevalence countries, that latent
infection could be recognized by tuberculin testing,
and that nonspeciﬁc tuberculin reactivity was
common in certain geographic regions.
While knowledge of tuberculosis advanced with
the work of Villemin, Koch, von Pirquet, and
others, the tidal wave of disease in Europe and
North America ebbed. Mortality rates began to
decline in the early and mid-19th century.33,34,53–55
The explanation for this decline remains elusive.
Improved social and living conditions, herd immu-
nity resulting from natural selection of a geneti-
cally more resistant population, and improved
nutrition have all been offered as hypotheses, but
none of these appears adequate to wholly explain
the observed decline in tuberculosis rates.55 Falling
case rates were accompanied by an apparent shift
of disease occurrence to older individuals. That this
shift in age-speciﬁc incidence resulted as a legacy
of high infection rates in youth of now elderly
cohorts was demonstrated ﬁrst by Anvord and
shortly thereafter and independently by Frost.56,57
The decline has continued to the present time,
largely unaffected by the institution of public
health programs or effective chemotherapy, and
today tuberculosis incidences in Europe and North
America are at historic lows. Elsewhere, especially
in Subsaharan Africa where it is fueled by AIDS, the
tuberculosis epidemic continues unabated.
Regardless of the secular trends that showed a
declining tuberculosis problem, ill patients sought
comfort and relief. They turned to spas or
sanitaria.24,58 In 1859 Herman Brehmer opened his
Heilenstat in the Silesian Mountain village of
Gobersdorf where he emphasized a regimen of
rest, a rich diet, and carefully supervised exercise.
This sanatorium is generally considered the ﬁrst
such facility devoted to the treatment of tubercu-
losis, although Harriet Ryan Albee had opened the
Channing Home in the basement of a Boston church
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sanatorium in Falkenstein, near Frankfort, Ger-
many, in 1867. The ﬁrst sanatorium in North
America was opened in Asheville, North Carolina,
by Joseph Gleitsman. Edward Livingston Trudeau’s
Adirondack Cottage Sanitarium followed in 1884.
These retreats isolated tuberculosis sufferers not
only from those whom they might infect but
also from matters of the current world, as
poignantly portrayed by Thomas Mann in The Magic
Mountain.59
Sanatorium care certainly comforted and brought
peace of mind to many sufferers. In 1907 the
British Journal of Tuberculosis, the antecedent of
Respiratory Medicine, led off its ﬁrst issue with
an editorial, presumably written by the editor,
T.M. Kelynacky
Fads and fancies have gathered about so called
‘‘open-air’’ treatment, and impossible claims
have been made by inexperienced enthusiasts as
to the almost miraculous efﬁcacy accruing from
sanatorium residence. In spite of all exaggera-
tions and failures, there can be no doubt but
that the maintenance of a strictly hygienic
course of life offers the best means known to
modern medical science for dealing effectually
with tuberculosis.60
Whether sanatorium care changed the ultimate
outcome for diseased persons is not clear. A 5-year
follow-up study by G. Lissant Cox of more than 4000
patients in Lancashire County, England published in
the British Journal of Tuberculosis in 1923 com-
pared patients treated at home with those treated
in sanatoria.61 Among those patients who were
sputum-negative at admission, 14% of those treated
in sanatoria had died, whereas 38% of those treated
at home had succumbed. Among sputum-positive
patients, the same death rates were 61% and 81%.
The study may have been inﬂuenced by selection
bias, but its results are dramatic. A careful and
statistically sophisticated review of experience at
New York State sanatoria similarly found that
patients with minimal disease did well; those with
far advanced disease did not.62 Overall the cure
rate in New York sanatoria did not differ greatly
from the spontaneous cure rates summarized by
Grzybowski and Enarson.63
If rest was good for the tuberculous body,
perhaps rest of diseased lungs would be beneﬁcial.
Thus, pulmonary collapse therapy became popular,
especially for cavity closure.24 Sand bags were
sometimes used to splint one side of the chest, and
Robert Louis Stevenson wrote A Child’s Garden of
Verse with his left hand while his right arm was
strapped to his chest in an attempt to control hishemoptysis. In the late 19th and early 20th
centuries surgical collapse procedures were widely
used in the management of cavitary tuberculosis.
Cavity closure, hopefully with sterilization of
sputum, was the usual goal of this therapy.
In 1696, Giorgio Baglivi described improvement
in a tuberculous patient who incurred a pneu-
mothorax following a sword wound. The ﬁrst
successful therapeutic pneumothorax was induced
by F.H. Ramadge in London in 1834; he reported
cure of his patient. Carlo Forlanini carefully
documented his results with artiﬁcial pneumothor-
ax in 1894, and thereafter the procedure became
widely used. For lower lobe cavities, pneumoper-
itoneum was employed. It is probable that pneu-
mothorax was a useful therapy, primarily because it
often resulted in cavity closure and sputum
conversion to negative. However, there are no
controlled studies of its efﬁcacy—it is difﬁcult to
know how one would design such trials—and one
must rely on reviews of series of treated patients.
Writing in the British Journal of Tuberculosis in
1939, Oli Hjaltested and Kjeld To¨rning reported the
outcome of 191 patients treated between 1925 and
1931 with pneumothorax at the O¨resund Hospital in
Copenhagen.64 All were sputum-positive at the
time of initiation of the pneumothorax. At follow-
up, 65 had died, 11 were still sputum-positive,
eight were still being treated but were otherwise
well, and 107 had been discharged from treatment
and were well. In 1951, Roger Mitchell published a
series of articles reporting the outcome of 557
patients treated at the Trudeau Sanatorium in
Saranac Lake, New York with pneumothorax be-
tween 1930 and 1939. Of these, 326 were working
and well, 60 were chronically ill with tuberculosis
or disabled, and 119 were dead of tuberculosis.65
Thoracoplasty was ﬁrst introduced by Swiss
surgeon De Ce´renville and further popularized by
Norwegian physicians Ludloff Brauer and P.L.
Friedrich. It gained favor because it could be done
without entering the pleural space and incurring
the risk of tuberculous empyema. Harvey Beard
reviewed the results of 100 patients in an article
published in the British Journal of Tuberculosis and
Disease of the Chest in 1951.66 Cavity closure and
sputum conversion was achieved in 63 of these
patients. In 1937, Samuel Freedlander and Sidney
Wolpaw reported their results in patients in Cleve-
land, OH, comparing the outcomes of 85 patients
selected for thoracoplasty who accepted the
procedure with 58 who refused it.67 Cavity closure
was achieved in 66% of those who underwent
thoracoplasty and only 17% of those who refused it.
If tuberculosis was infectious and if sanatorium
care could improve the health of its victims and
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then tuberculosis was a matter of public health
concern. As a 22-year-old undergraduate college
student at Cornell University in Ithaca, New York, in
1881, Herman Biggs was required to write a thesis.
He chose to write on public health, an emerging
and still rudimentary discipline. After hailing Koch’s
discovery of the tubercle bacillus as the ‘‘grandest
discovery of the age,’’ he concluded, ‘‘Then let us
join in a cordial hail to the coming centuries, to the
time when zymotic diseases have become almost
traditional, when life shall be prolonged and the
enjoyment of health and immunity from suffering
shall be almost universal through the advances in
Preventive Medicine and the prevalence and ob-
servance of National Sanitary Regulations.’’68 Biggs
pursued a career in medicine and public health and
became Chief Medical Ofﬁcer for New York City and
later Health Commissioner for the State of New
York.29 In 1889, Biggs was instrumental in convin-
cing the city of New York to require reporting of
tuberculosis cases by care providers. Both the
public and the medical profession resisted this
move, but Koch noted it and congratulated Biggs in
a letter in 1906. ‘‘We have much to learn,’’ he
wrote, ‘‘from what in my opinion appear to be
procedures adapted in an extraordinarily practical
and adequate manner to the control of tuberculosis
as you have carried them out in New York.’’68
A more direct approach to the public health
challenges of tuberculosis was taken by Albert
Calmette and his associate Camille Gue´rin.69,70
They set out to develop a vaccine against tubercu-
losis. At the newly established Pasteur Institute of
Lille, where Calmette was the founding director,
they undertook a herculean effort to attenuate
M. bovis for use as a vaccine. Surviving the
disruptions of World War I, Calmette, now in Paris,
was ready to try the vaccine, BCG (Bacille Calm-
ette-Gue´rin) in 1921. An infant born of a mother
dying of pulmonary tuberculosis and placed in the
care of a tuberculous grandmother was the ﬁrst
recipient. The child survived and did not develop
tuberculosis. Over the next 7 years, more than
100,000 children were immunized, including Calm-
ette’s children. The vaccine was readily accepted
in much of Europe. It was not widely used in
Britain, however, and in 1928 Calmette published a
paper in the British Journal of Tuberculosis arguing
for its use.71
As noted previously, tuberculosis incidences were
falling rapidly in Europe during the ﬁrst half of the
20th century, but the ravages of World War I led to
a resurgence of the disease. The American Red
Cross sponsored an evaluation trip to France by
Herman Biggs in 1916–17. ‘‘Tuberculosis offers aproblem of stupendous magnitude in France,’’ Biggs
reported. ‘‘If the war were to end now, there would
be between 400,000 and 500,000 cases of tubercu-
losis to be cared for, and practically no facilities to
deal with them.’’68,72 Again, the British Journal of
Tuberculosis took note of the problem.72 With
support from the Rockefeller Foundation and
French voluntary agencies the Comite´ National de
De´fense contre la Tuberculose mounted a country-
wide public health campaign that brought public
health measures to all of France.73
During World War I, both the allies and Germans
screened their military recruits for tuberculosis
using chest radiographs. After the war there
followed three decades of mass radiographic
screening for tuberculosis detection in civilian
populations. In 1945 in the British Journal of
Tuberculosis and Diseases of the Chest, T.W. and
Mostyn Davies described a survey undertaken
throughout Wales that reached 21,627 persons.74
From this large number, 133 cases of tuberculosis
were found (0.6%). Small yields of this sort led to
the abandonment of mass radiography as less
productive than contact investigation.
In 1948, a remarkable campaign to control
tuberculosis with sponsorship by UNICEF and the
Danish Red Cross was undertaken with Johannes
Holm as its director.75 The effort was based on
tuberculin testing followed by BCG vaccination of
nonreactors. It began in Poland, but soon spread to
other European countries and ultimately to Ecua-
dor. During the next 3 years, nearly 30 million
persons were tuberculin tested and nearly 14
million vaccinated with BCG. The program was, in
fact, the ﬁrst disease control program undertaken
by an agency of the World Health Organization.
In 1974 the WHO Expert Committee on Tubercu-
losis issued its Ninth Report, a document that
provided policy guidelines for tuberculosis control
for the next 2 decades.76 It discouraged both
radiographic screening and tuberculin testing and
promoted sputum microscopy of symptomatic
individuals and those at risk. It advocated ambula-
tory therapy and recommended against hospitaliza-
tion of tuberculosis patients. It strongly encouraged
BCG vaccination, setting a target of 70–90% cover-
age for all persons less than 15–20 years of age.
Today, the WHO continues to mount programs for
tuberculosis control, but it no longer recommends
BCG vaccination except for newborns. In the United
States, where BCG has not been widely used,
tuberculosis control programs emphasize treatment
of latently infected individuals.
Edward Livingston Trudeau, famous for his
Adirondack Cottage Sanitarium, was a remarkable
man. A victim of tuberculosis himself and the
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established a research laboratory in conjunction
with his Saranac Lake sanatorium and carried out
many studies examining the efﬁcacy of his treat-
ment. In a communication to the British Journal of
Tuberculosis published shortly after his death from
tuberculosis, he commented on the prospect of
chemotherapy for tuberculosis.77
My faith in the possibilities of chemotherapy for
tuberculosis is based simply on what Ehrlich has
demonstrated as possible in syphilis—namely,
that a chemical compound could be discovered
which killed the germ without injuring the
celly. I see no reason why what has been
accomplished in the treatment of syphilis should
not be attained in tuberculosis.
Three decades later the outlook for tuberculous
patients and the history of tuberculosis changed
dramatically with the introduction of the che-
motherapy Trudeau foretold. The discovery of para-
amino salicylic acid (PAS) by Jorgen Lehmann in
1943 and of thiosemicarbazone by Gerhard Domagk
during wartime Germany and culminating in 1945
yielded the ﬁrst therapeutic agents with efﬁcacy in
the treatment of tuberculosis.78 Both were dis-
appointing only bacteriostatic. In 1944 Albert
Schatz, Elizabeth Bugie, and Selman Waksman
reported the insolation of streptomycin, the ﬁrst
antibiotic and ﬁrst bactericidal agent effective
against M. tuberculosis.24,78,79 Within a few months
it had been used with dramatic results to treat a
young woman with tuberculosis.80 Limited supplies
led to limited distribution, and streptomycin was
slow to reach Europe. The British Medical Research
Council used the ﬁrst available supplies in 1946 to
conduct a pioneering randomized, controlled study
of the efﬁcacy of the drug.81 Fifty-ﬁve treated
patients were compared with 52 control patients.
Improvement was noted in 31 treated and only 16
untreated patients. Deaths occurred in 12 of those
treated and 24 of those not given the drug. It was
not until 1950, however, that the ﬁrst report of
streptomycin treatment appeared in the British
Journal of Tuberculosis and Diseases of the Chest.82
Isoniazid, the ﬁrst oral mycobactericidal drug,
followed in 1952 and rifamycins in 1957. A new era
of tuberculosis treatment had dawned. Sanatoria
closed. Truly effective public health measures
became possible. Treatment was increasingly ex-
panded to include those with latent tuberculous
infections. The history of tuberculosis control
entered on a new chapter. Treatment to cure
became the goal sought for every afﬂicted person
in the world.References
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